



Vita Life Sciences Limited
ABN 35 003 190 421
Suite 630
1 Queens Road Melbourne
Victoria 3004 Australia
T 61 3 9867 2811
F 61 3 9820 5957
www.vitalifesciences.com

**Vita Life Sciences Limited (“Vita Life”)
Annual General Meeting 23 May 2008**

Summary of Managing Director’s Address

Opening:

Mr Eddie Tie highlighted the milestones in 2007 being:

- Company’s listing on the ASX;
- Positive shareholders’ funds;
- Reduction in borrowings;
- Expansion into new markets (China, Indonesia & Thailand). Mr Tie added growth from these markets would eventuate in the near future;
- Established investment division. Mr Tie commented the objective of investment division is for diversification purpose;
- Successful divestment of Group’s former medical division.

Financial highlights:

Sales in 2007 improved 6.3% with growth in Australia, Singapore, Malaysia approximately 2.0%, 8.0% and 16.0% respectively. Gross profit, EBIT and net loss had improved, excluding the one-off gain from divestment of former medical division.

Normalised operating performance:

Normalised performance of the Group had improved compared to previous corresponding year. Mr Tie commented established operating units were profitable but was offset by costs of establishing new operating units.

Financial position:

Shareholders’ funds were positive in December 2007 as a result of capital raising exercise and profit from divestment of former medical division. In addition, gearing had improved to 28.0%.

Cash Flow of the Group:

Group successfully maintained stronger positive operating cash flow from previous year. Mr Tie added proceeds from divestment of former medical division and capital raising exercise were used to reduce borrowings.

Development of the Health division:

Mr Tie discussed the developments and growth of the established and new business units of the Group.

Development of Investment division:

Mr Tie discussed the progress of investment division’s property development project in Malaysia. The development project is expected to be profitable in 2008 and contribute substantial cash.

Forecast for 6 months ended 30 June 2008:

Sales are forecast to be approximately 20% higher than previous corresponding period. Established business units in Australia, Singapore and Malaysia are forecast to be profitable. However, the costs of establishing new business units in Thailand, China and Malaysia and compliance costs of being a listed company are forecast to result in the Group reporting an EBIT loss of \$0.50 million for the half.

Outlook for the year ending 31 December 2008

The Group is forecasting a small profit for 2008 with established business units continuing to contribute positively and improved performance from the new business units.



Vita Life Sciences

Shareholder Presentation

Annual General Meeting

23 May 2008



Chairman's Welcome

Welcome to the
Annual General Meeting of
Vita Life Sciences Limited



Agenda

1. **Welcome**
2. **Managing Directors' Review**
3. **Ordinary and Special Business:**
Resolutions 1 - 8
4. **Question Time**
5. **Close**



Highlights

- **Listed on ASX**
- **Positive shareholders' funds**
- **Substantial reduction in borrowings**
- **Platform established for growth**
- **Established investment division**
- **Completed divestment of former medical division**

Financial Highlights



Financial Year Ended (A\$ million)	31-Dec-07	31-Dec-06	% Change
Sales	11.84	11.13	6.3%
Gross Profit	6.78	5.89	15.1%
EBIT	(0.02)	8.69 *	<100%
Net (loss)/ profit	(0.20)	9.67 *	<100%

* Incl one-off profit from divestment of assets of \$11.8 million

- Positive sales growth & improved gross profit
- Comparison of profit/ loss not relevant – 2006 results include profit from divestment

Normalised Operating Performance



Financial Year Ended (A\$ million)	31-Dec-07	31-Dec-06	% Change
Sales revenue*	11.84	11.13	6.3%
Cost of sales	(5.06)	(5.24)	3.5%
Gross Profit	6.78	5.89	15.1%
Marketing expenses	(1.75)	(1.59)	-10.5%
Employees and consultants expenses	(3.88)	(3.67)	-5.7%
Net finance expenses	(0.30)	(0.38)	19.4%
Other expenses	(1.10)	(1.22)	9.5%
Loss after tax	(0.26)	(0.96)	73.3%


* Excludes any contribution from divested Cyclopharm Ltd group of companies

(1) Figures above reflects ongoing normalised costs

- Loss as a result of costs in establishing new business units



Sales by Geographical segment



Financial Position



Financial Year (A\$ million)	31-Dec-07	31-Dec-06	% Change
Total assets	6.73	12.96	-48.1%
Borrowings	(0.82)	(14.35)	94.3%
Total Liabilities	(3.85)	(15.10)	74.5%
Total equity	2.88	(2.14)	>100%

- Positive shareholders' funds
- Substantial reduction in borrowings



Summary of cash flow

Financial Year (A\$ million)	31-Dec-07	31-Dec-06	% Change
Cashflow from operations activities	2.17	2.16	0.6%
Net finance expense (paid)/ received	(1.42)	(1.64)	13.5%
Net operating cash flow	0.75	0.52	45.3%
Capital expenditures	(0.19)	(0.23)	19.7%
Sale of investment & fixed assets	0.01	16.34	-99.9%
Net proceeds shares issued	5.93	0.90	>100%
Net (repayment of)/ proceeds from borrowings	(7.91)	(16.54)	52.2%
Net movement in Cashflow position	(1.41)	0.98	<100%

- Continued positive operating cash flow
- Substantial repayment of borrowings

Health Division's Product Brands



Health Division 2007: Brand equity enhancement



- **Continue to grow market position in 3 established markets**
- **Launched VitaLife, the Multi-Level-Marketing unit**
- **Launched Pharma Direct, affordable supplements brand**
- **Launched VitaHealth into Thailand**
- **Obtained approvals to expand Herbs of Gold into China**
- **Established legal representative office in Vietnam & Indonesia**



Health Division 2007: Brand equity enhancement (contd.)



- **Expanded our marketing channels:**
 - ❖ **Over-the-counter (OTC): Pharmacy and health food channels;**
 - ❖ **Multi-Level-Marketing (MLM): Direct marketing to consumers;**
 - ❖ **Pharma Direct: Affordable Supplements Direct to Practitioners**

Investment Division

- **First investment: New property development project**
 - ❖ **372 units of houses and shops project in Malaysia**
 - ❖ **Estimated gross development value: \$30.0 mil**
 - ❖ **Launched Phase 1 in August 2007**
 - ❖ **Group has 20.1% share of profit**





Jan – June 2008

- **Sales up 20% 1st half 08**
- **Established business units profitable**
- **Low gearing \$0.75 m to \$1.00 m debt**
- **EBIT for half year June 08 loss of \$0.50m:**
 - ❖ **Established business profitable offset by costs of establishing new business units**
 - ❖ **Compliance costs of a listed company for 1st time**



Outlook for 2008

- **Group to make small profit in FY2008**
- **Continue to develop new business units**
- **China business to contribute**
- **Sustainable competitive advantages**
- **Remain confident of our strategy:**
 - ❖ **Expanding existing & building new businesses**



Agenda

1. **Welcome**
2. **Managing Directors' Review**
3. **Ordinary and Special Business:
Resolutions 1 - 8**
4. **Question Time**
5. **Close**



Proxy Summary

Resolution	Business	For	Against	Abstain
1	Adoption of Remuneration Report	25,331,380	38,197	125
2	Election of Director	24,889,699	2,053	477,950
3	Non-marketable parcels & Small Holding Sale facility	25,361,429	7,620	653
4	Underwriting fee to CVCV	17,495,552	38,505	7,835,645
5	Share issue to VBH	25,363,698	5,226	778
6	Issue of Options to BW	19,284,701	84,876	6,000,125
7	Dividend Reinvestment Plan	25,367,524	2,053	125
8	On-market share buy-back	25,361,090	7,959	653



Summary

- **Share purchase plan with aim to raise \$2 million in new capital to fund continued expansion of new business units**
- **New business units' initiatives will lead to stronger & profitable group**



Thank You